Trial · NCT03689374
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Glycated Haemoglobin (HbA1c) | Semaglutide | -1.5 | Standard Deviation 1.0 | Percentage of HbA1c | |
| Change From Baseline in Glycated Haemoglobin (HbA1c) | Insulin Aspart | -1.2 | Standard Deviation 1.0 | Percentage of HbA1c | |
| Time to First Event Adjudication Committee (EAC)-Confirmed Severe Hypoglycaemic Episode American Diabetes Association (ADA) From Randomization up to Week 52 | Semaglutide | 0.4 | First event per 100 years of exposure | ||
| Time to First Event Adjudication Committee (EAC)-Confirmed Severe Hypoglycaemic Episode American Diabetes Association (ADA) From Randomization up to Week 52 | Insulin Aspart | 0.7 | First event per 100 years of exposure | ||
| Time to First Event Adjudication Committee-confirmed Severe Hypoglycaemic Episode (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening Randomization up to Week 52 | Semaglutide | 0.2 | First event per 100 years of exposure | ||
| Time to First Event Adjudication Committee-confirmed Severe Hypoglycaemic Episode (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening Randomization up to Week 52 | Insulin Aspart | 0.4 | First event per 100 years of exposure | ||
| Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) From Randomization to Week 52 | Semaglutide | 4 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) From Randomization to Week 52 | Insulin Aspart | 7 | Episodes | ||
Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose (BG) Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose Less Than (<) 3.1 mmol/L (56 mg/dL)) From Randomization to Week 52 | Semaglutide | 254 | Episodes | ||
Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose (BG) Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose Less Than (<) 3.1 mmol/L (56 mg/dL)) From Randomization to Week 52 | Insulin Aspart | 1744 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose <= 3.9 mmol/L (70 mg/dL)) From Randomization to Week 52 | Semaglutide | 1420 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose <= 3.9 mmol/L (70 mg/dL)) From Randomization to Week 52 | Insulin Aspart | 5616 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening From Randomization to Week 52 | Semaglutide | 2 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening From Randomization to Week 52 | Insulin Aspart | 4 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe (ADA) or Clinically Significant Hypoglycaemic Episodes (Plasma Glucose < 3.0 mmol/L (54 mg/dL)) From Randomization to Week 52 | Semaglutide | 339 | Episodes | ||
| Number of Event Adjudication Committee-confirmed Severe (ADA) or Clinically Significant Hypoglycaemic Episodes (Plasma Glucose < 3.0 mmol/L (54 mg/dL)) From Randomization to Week 52 | Insulin Aspart | 2270 | Episodes | ||
| Daily Basal Insulin Dose at Week 52 | Semaglutide | 35.8 | Standard Deviation 19.4 | Units of insulin | |
| Daily Basal Insulin Dose at Week 52 | Insulin Aspart | 40.7 | Standard Deviation 22.0 | Units of insulin | |
| Total Daily Insulin Dose at Week 52 | Semaglutide | 35.8 | Standard Deviation 19.4 | Units of insulin | |
| Total Daily Insulin Dose at Week 52 | Insulin Aspart | 77.7 | Standard Deviation 40.0 | Units of insulin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03689374/results